Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Warner-Lambert

This article was originally published in The Tan Sheet

Executive Summary

Bequests six- month extension on implementation of OTC anorectal drug products amendment to have more time "to deplete current inventories of existing labels" for witch hazel products, the company said in an Aug. 15 letter to FDA. In June, FDA amended the final monograph for OTC anorectal drugs to change the name of "Hamamelis water" to "witch hazel" in order to be consistent with changes made in the U.S. Pharmacopeia official compendium ("The Tan Sheet" June 6, In Brief). The company stated that all of its "current labels denote Hamamelis Water followed by Witch Hazel in parenthesis," and requested that the effective date of the regulation be extended from Jan. 1, 1995 to June 3, 1995

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS083173

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel